Consun Pharmaceutical Tightens ESG Governance With Updated Committee Mandate

Consun Pharmaceutical Group Ltd. ( (HK:1681) ) has shared an announcement.

Consun Pharmaceutical Group Ltd. has formalised and updated the terms of reference for its Environmental, Social and Governance (ESG) Committee, effective 23 December 2025, to align with Hong Kong Listing Rules and strengthen oversight of ESG and climate-related issues. The Board-appointed committee, chaired by the board chairman and supported by the company secretary, will comprise at least two directors with ESG and climate expertise, meet at least annually, and is empowered to obtain information from employees, external parties and professional advisers at the company’s expense for ESG reporting and governance. By institutionalising these structures and powers, the company is reinforcing its ESG governance framework and signalling to regulators, investors and other stakeholders that it is enhancing its capacity to manage climate risks, comply with disclosure requirements and respond to rising market expectations on sustainability.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

More about Consun Pharmaceutical Group Ltd.

Consun Pharmaceutical Group Ltd. is a Cayman Islands–incorporated company listed in Hong Kong and engaged in the pharmaceutical industry, focusing on the development, production and sale of medicines and related healthcare products. The group operates through a network of subsidiaries and is subject to the Hong Kong Listing Rules, including evolving requirements on environmental, social and governance (ESG) reporting and climate-related disclosure.

Average Trading Volume: 2,304,458

Technical Sentiment Signal: Buy

Current Market Cap: HK$13.18B

For a thorough assessment of 1681 stock, go to TipRanks’ Stock Analysis page.